Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.

Reisenbichler ES, Horton D, Rasco M, Andea A, Hameed O.

Am J Clin Pathol. 2012 Jan;137(1):102-10. doi: 10.1309/AJCPLNHINN9O6YSF.

PMID:
22180483
2.

mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.

Bernet L, Martinez Benaclocha M, Castera C, Cano Muñoz R, Sevilla F, Alba J, de Dios Barranco J, Cordoba A, Garcia-Caballero T, Hardisson D, de Francisco Hernandez JM, Lazaro JM, Polo L, Riu F, Rezola R, Rojo F, Ruiz I, Hernándiz A, de la Cámara de Las Heras JM, Coupe VM.

Diagn Mol Pathol. 2012 Jun;21(2):84-92. doi: 10.1097/PDM.0b013e3182360b0a.

PMID:
22555091
3.
4.
5.
6.
7.

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).

Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY.

Pathol Int. 2010 Jul;60(7):510-5. doi: 10.1111/j.1440-1827.2010.02553.x.

PMID:
20594272
8.
9.

Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.

Schiavon BN, Jasani B, de Brot L, Vassallo J, Damascena A, Cirullo-Neto J, Ivanildo Neves J, Augusto Soares F, Gobbi H, Malagoli Rocha R.

Am J Surg Pathol. 2012 Oct;36(10):1489-96. doi: 10.1097/PAS.0b013e3182635987.

PMID:
22982892
10.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

11.

Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR.

Histopathology. 2011 Nov;59(5):984-92. doi: 10.1111/j.1365-2559.2011.04037.x.

PMID:
22092410
12.

HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?

Bethune GC, Mullen JB, Chang MC.

Am J Clin Pathol. 2013 Oct;140(4):588-92. doi: 10.1309/AJCPZSV2W1CPGRJW.

PMID:
24045558
13.
15.

Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

Nie X, He J, Li Y, Pan DZ, Pan HX, Weng MX, Yang XP, Liu CP, Huang T.

J Huazhong Univ Sci Technolog Med Sci. 2013 Jun;33(3):379-84. doi: 10.1007/s11596-013-1128-5. Epub 2013 Jun 17.

PMID:
23771664
16.

Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.

Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, Lonzo M, Wiktor AE, Dogan A, Jenkins RB.

Am J Clin Pathol. 2013 Feb;139(2):144-50. doi: 10.1309/AJCP13GJAOJAYJMW.

PMID:
23355198
17.
19.

Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY, Apple SK.

Am J Clin Pathol. 2011 Nov;136(5):754-61. doi: 10.1309/AJCP99WZGBPKCXOQ.

PMID:
22031314
20.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120

Supplemental Content

Support Center